Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
The aggregate gross proceeds to the Company from the Offering are expected to be approximately $10.0 million, before deducting the placement agent fees and other offering expenses payable by the ...
HOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV
HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HI ...
Cogent Biosciences to Participate in the Guggenheim Biotech Conference
WALTHAM, Mass. and BOULDER, Colo., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COGT), a biotechnology company focused on ...